April 6, 2022
FDA Approves Novartis’s Vijoice as First and Only Treatment for Select Patients with PIK3CA-Related Overgrowth Spectrum (PROS)
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Novartis-s Vijoice (alpelisib) for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.